Two experimental AstraZeneca drugs show promise in ovarian cancer

May 31, 2014 11:06 AM

2 0

Two experimental AstraZeneca drugs show promise in ovarian cancer

(Reuters) - A combination of two drugs developed by AstraZeneca Plc, olaparib and cediranib, was shown in a mid-stage study to nearly double the length of time certain ovarian cancer patients lived without their disease getting worse.

After spurning a $118 billion takeover approach from Pfizer Inc, Britain's AstraZeneca is aiming to show investors at this weekend's meeting of the American Society of Clinical Oncology in Chicago that its pipeline of cancer drugs offers an opportunity for future sales growth.

Also watch: How to watch College Football Playoff selection show announcement: Live stream, time, channel

Read more

To category page

Loading...